



The Medicines Patent Pool (MPP) and Unitaid are honoured to invite you to a Satellite Symposium during the 22nd International AIDS Conference.

Meet the manufacturers of HIV and HCV treatments: challenges and opportunities for treatment scale-up

Manufacturers, licensees of the MPP, will discuss the new adult and paediatric formulations they are currently developing or have recently introduced; roll-out plans and timelines; existing challenges and opportunities; and market trends.

An interactive Q&A session will follow.

Tuesday 24 July 2018 from 18:30 to 20:30

Emerald room

RAI Amsterdam Convention Center

All conference participants are welcome to join. Light refreshments will be served 30 minutes **before** the event.

Access the link to register



PROGRAMME

18:00-18:30 Light refreshments will be served.

18:30-19:00 Opening remarks by co-chairs

Charles Gore, Executive Director, Medicines Patent Pool (MPP) Alexandra Volgina, Program Manager, GNP+

Introductory presentations

From pipelines to frontlines and the role of manufacturers: challenges and opportunities in facilitating the introduction of new HIV and HCV treatments in low- and middle-income countries Robert Matiru, *Director of Operations, Unitaid*

Accelerating access to new WHO recommended generic medicines and formulations Esteban Burrone, Head of Policy, MPP; Aastha Gupta, Head of Business Development a.i., MPP

Transition to new treatments and formulations

Francisco Popular Department of HIV/AIDS World Hos

Françoise Renaud, Department of HIV/AIDS, World Health Organization

19:00-20:30 Panel discussion moderated by co-chairs

Arvind Kanda, Senior Vice President - Head HIV and Infectious Diseases, API, South Africa and Sub-Saharan Africa, Mylan

Balaji UD, Senior Director, Global HIV/AIDS Initiatives, Emcure Pharmaceuticals
Chandrakanth Chereddi, Executive Director & Head - Generics FDF Division, Laurus Labs
Jos Perriëns, Strategic Advisor Access Markets, Hetero Corporate
Shailesh Pednekar, Senior Vice President – International Business, Macleods
Umesh K, Vice President and Business Unit Head, Global Anti-Virals, Aurobindo Pharma

Q&A session Closing remarks